NewAmsterdam Pharma Company N.V.

NasdaqGM NAMS

NewAmsterdam Pharma Company N.V. EBITDA Margin for the year ending December 31, 2023: -1,385.76%

NewAmsterdam Pharma Company N.V. EBITDA Margin is -1,385.76% for the year ending December 31, 2023, a -40,009.78% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

NewAmsterdam Pharma Company N.V. EBITDA Margin for the year ending December 31, 2022 was -3.45%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	62
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Key trends

Past 5 years